Hoth Therapeutics

186 articles about Hoth Therapeutics

• Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm

  4/5/2021

  Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company's method for inhibiting formation of biofilms.

• Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic

  3/23/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002 , a novel therapeutic targeted for the treatment of COVID-19 . 

• 

  2021 Biopharma Update on the Novel Coronavirus: March 23

  3/23/2021

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.

• Hoth Therapeutics to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021

  3/22/2021

  Robb Knie, CEO, will also participate in a panel discussion entitled, 'Coming Together to Address Unmet Medical Needs'

• Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20th

  3/19/2021

  Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company , today announced an exclusive interview featuring Robb Knie , CEO, airing on The RedChip Money Report on the Bloomberg Television U.S. on Saturday, March 20th at 7 p.m. local time across the United States .

• Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006

  3/17/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute ("UCRI") to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.

• Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease

  3/11/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn's disease patients.

• Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  3/10/2021

  Hoth Therapeutics, Inc., a patient focused clinical stage biopharmaceutical company, announced the closing of its previously announced private placement of common stock and warrants to purchase shares of common stock priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of $15.0 million.

• Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  3/8/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreement with certain institutional and accredited investors for the issuance and sale of an aggregate of 7,594,937  shares of its common stock (or common stock equivalent in lieu thereof)

• Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies

  3/3/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19.

• Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

  3/1/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

• Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

  2/26/2021

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company , today announced it has expanded its licensing agreement from North Carolina State University (" NC State ") to include the worldwide development and commercialization of treatments targeting mast cell derived cancers and anaphylaxis. 

• Hoth Therapeutics Retains RedChip to Increase Investor Awareness

  2/25/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts.

• Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment

  2/24/2021

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced it has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent Alzheimer's disease. 

• Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients

  2/23/2021

  Hoth intends to pursue FDA Expedited Programs, such as Breakthrough Designation, pending generation of future clinical study data for HT-001

• Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)

  2/18/2021

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company , today announced that it intends to expand the development of the HT-003  active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel disease

• Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference

  2/17/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced that it will be presenting at the upcoming the Diamond Equity Research Growth Invitational virtual investor conference on February 24, 2021.

• Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv

  2/10/2021

  Hoth Therapeutics today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whitepaper in bioRxiv regarding COVID-19 SARS-CoV-2 titled, "Transformations, Comparisons, Analysis of Down to Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein including the UK Variant B.I.I.7."

• Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients

  2/8/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company , today announced that it has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application

• Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline

  2/2/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications.